Molecular and Cellular Mechanisms of Antidepressant Action

Current Topics in Behavioral Neurosciences

Volumn 14, Issue , 2013, Pages 309-325

  Sharp, Trevor ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

5 HT; Antidepressant; Autoreceptors; Gene expression; Neural plasticity; Neurotrophic factors; Noradrenaline

Indexed keywords

ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DESIPRAMINE; DOPAMINE BETA MONOOXYGENASE; FIBROBLAST GROWTH FACTOR 2; FLUOXETINE; IMIPRAMINE; KETAMINE; MONOAMINE; NORADRENALIN; PAROXETINE; PINDOLOL; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN; VESICULAR GLUTAMATE TRANSPORTER 1;

5 HT1A RECEPTOR GENE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BDNF GENE; BRAIN DEVELOPMENT; BRAIN REGION; COMBINATION CHEMOTHERAPY; CREB GENE; DEPLETION; DEPRESSION; DRUG POTENTIATION; FGF2 GENE; GENE; GENE EXPRESSION; HUMAN; INTRACELLULAR SIGNALING; LIMBIC SYSTEM; MOLECULAR MEDICINE; MONOTHERAPY; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NONHUMAN; P11 GENE; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; RECEPTOR DOWN REGULATION; REMISSION; SEROTONINERGIC TRANSMISSION; TREATMENT OUTCOME; VEGF GENE; VGLUT1 GENE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; HUMANS; NEURONAL PLASTICITY; NEURONS; SIGNAL TRANSDUCTION;

EID: 84880079849     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2012_216     Document Type: Article

References (87)

1. 1A antagonists. Trends Neurosci 19(9):378-383.
2. Banasr M, Dwyer JM, Duman RS (2011) Cell atrophy and loss in depression: reversal by antidepressant treatment. Curr Opin Cell Biol 23(6):730-737.
3. Blendy JA (2006) The role of CREB in depression and antidepressant treatment. Biol Psychiatry 59(12):1144-1150.
4. Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15(7):220-226.
5. Calabrese F, Molteni R, Gabriel C, Mocaer E, Racagni G, Riva MA (2011) Modulation of neuroplastic molecules in selected brain regions after chronic administration of the novel antidepressant agomelatine. Psychopharmacology (Berl) 215(2):267-275.
6. Cappiello A, McDougle CJ, Malison RT, Heninger GR, Price LH (1995) Yohimbine augmentation of fluvoxamine in refractory depression: a single-blind study. Biol Psychiatry 38(11):765-767.
7. Castren E (2005) Is mood chemistry? Nat Rev Neurosci 6(3):241-246.
8. Castro ME, Harrison PJ, Pazos A, Sharp T (2000) Affinity of (±)-pindolol, (-)-penbutolol, and (-)-tertatolol for pre-and postsynaptic serotonin 5-HT(1A) receptors in human and rat brain. J Neurochem 75(2):755-762.
9. 1A receptor antagonist co-administration. J Neurochem 85(6):1480-1487.
10. Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA (2002) cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 22(8):3262-3268.
11. Conti B, Maier R, Barr AM, Morale MC, Lu X, Sanna PP, Bilbe G, Hoyer D, Bartfai T (2007) Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Mol Psychiatry 12(2):167-189.
12. Coppen A (1967) The biochemistry of affective disorders. Br J Psychiatry 113(504):1237-1264.
13. Covington HE III, Lobo MK, Maze I, Vialou V, Hyman JM, Zaman S, LaPlant Q, Mouzon E, Ghose S, Tamminga CA, Neve RL, Deisseroth K, Nestler EJ (2010) Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J Neurosci 30(48):16082-16090.
14. Cowen P, Harmer C (2009) Is it all monoamines? In: Pariante CM, Nesse RM, Nutt D, Wolpert L (eds) Understanding depression: a translational approach. OUP, Oxford, pp 171-180.
15. Cryan JF, O'Leary OF, Jin SH, Friedland JC, Ouyang M, Hirsch BR, Page ME, Dalvi A, Thomas SA, Lucki I (2004) Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc Natl Acad Sci U S A 101(21):8186-8191.
16. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR (1990) Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47(5):411-418.
17. Duman RS, Heninger GR, Nestler EJ (1997) A molecular and cellular theory of depression. Arch Gen Psychiatry 54(7):597-606.
18. Duman RS, Voleti B (2012) Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 35(1):47-56.
19. Duric V, Banasr M, Licznerski P, Schmidt HD, Stockmeier CA, Simen AA, Newton SS, Duman RS (2010) A negative regulator of MAP kinase causes depressive behavior. Nat Med 16(11): 1328-1332.
20. Egeland M, Warner-Schmidt J, Greengard P, Svenningsson P (2010) Neurogenic effects of fluoxetine are attenuated in p11 (S100A10) knockout mice. Biol Psychiatry 67(11):1048-1056.
21. Elizalde N, Pastor PM, Garcia-Garcia AL, Serres F, Venzala E, Huarte J, Ramirez MJ, Del Rio J, Sharp T, Tordera RM (2010) Regulation of markers of synaptic function in mouse models of depression: chronic mild stress and decreased expression of VGLUT1. J Neurochem 114(5): 1302-1314.
22. Elsayed M, Banasr M, Duric V, Fournier NM, Licznerski P, Duman RS (2012) Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression. Biol Psychiatry (in press).
23. Farley S, Dumas S, El Mestikawy S, Giros B (2012) Increased expression of the Vesicular Glutamate Transporter-1 (VGLUT1) in the prefrontal cortex correlates with differential vulnerability to chronic stress in various mouse strains: effects of fluoxetine and MK-801. Neuropharmacology 62(1):503-517.
24. Garcia-Garcia AL, Elizalde N, Matrov D, Harro J, Wojcik SM, Venzala E, Ramirez MJ, Del Rio J, Tordera RM (2009) Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1. Biol Psychiatry 66(3):275-282.
25. Gartside SE, Umbers V, Hajos M, Sharp T (1995) Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 115(6):1064-1070.
26. Gaska M, Kusmider M, Solich J, Faron-Gorecka A, Krawczyk MJ, Kulakowski K, Dziedzicka-Wasylewska M (2012) Analysis of region-specific changes in gene expression upon treatment with citalopram and desipramine reveals temporal dynamics in response to antidepressant drugs at the transcriptome level. Psychopharmacology (Berl) (in press).
27. Gelenberg AJ, Chesen CL (2000) How fast are antidepressants? J Clin Psychiatry 61(10):712-721.
28. Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS (2009) Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 34(11):2459-2468.
29. Harmer CJ (2008) Serotonin and emotional processing: does it help explain antidepressant drug action? Neuropharmacology 55(6):1023-1028.
30. Harmer CJ, Goodwin GM, Cowen PJ (2009) Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry 195(2): 102-108.
31. Hayward G, Goodwin GM, Cowen PJ, Harmer CJ (2005) Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms. Biol Psychiatry 57(5):517-524.
32. Holmes A, Yang RJ, Murphy DL, Crawley JN (2002) Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology 27(6):914-923.
33. 1A/B receptor antagonist/5-HT transport inhibitor SB-649915-B. Psychopharmacology (Berl) 192(1):121-133.
34. Karpova NN, Pickenhagen A, Lindholm J, Tiraboschi E, Kulesskaya N, Agustsdottir A, Antila H, Popova D, Akamine Y, Bahi A, Sullivan R, Hen R, Drew LJ, Castren E (2011) Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science 334(6063): 1731-1734.
35. Kobayashi K, Ikeda Y, Sakai A, Yamasaki N, Haneda E, Miyakawa T, Suzuki H (2010) Reversal of hippocampal neuronal maturation by serotonergic antidepressants. Proc Natl Acad Sci U S A 107(18):8434-8439.
36. Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455(7215): 894-902.
37. Larsen MH, Rosenbrock H, Sams-Dodd F, Mikkelsen JD (2007) Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine. Eur J Pharmacol 555(2-3):115-121.
38. Lindefors N, Brodin E, Metsis M (1995) Spatiotemporal selective effects on brain-derived neurotrophic factor and trkB messenger RNA in rat hippocampus by electroconvulsive shock. Neuroscience 65(3):661-670.
39. Lindholm JS, Autio H, Vesa L, Antila H, Lindemann L, Hoener MC, Skolnick P, Rantamaki T, Castren E (2012) The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf(+)/(-) heterozygous null mice. Neuropharmacology 62(1):391-397.
40. Lominac KD, Oleson EB, Pava M, Klugmann M, Schwarz MK, Seeburg PH, During MJ, Worley PF, Kalivas PW, Szumlinski KK (2005) Distinct roles for different Homer1 isoforms in behaviors and associated prefrontal cortex function. J Neurosci 25(50):11586-11594.
41. Lopez JP, Mamdani F, Labonte B, Beaulieu MM, Yang JP, Berlim MT, Ernst C, Turecki G (2012) Epigenetic regulation of BDNF expression according to antidepressant response. Mol Psychiatry (in press).
42. Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S, Lambas-Senas L, Wiborg O, Haddjeri N, Pineyro G, Sadikot AF, Debonnel G (2007) Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 55(5):712-725.
43. Mannoury la Cour C, Boni C, Hanoun N, Lesch KP, Hamon M, Lanfumey L (2001) Functional consequences of 5-HT transporter gene disruption on 5-HT(1a) receptor-mediated regulation of dorsal raphe and hippocampal cell activity. J Neurosci 21(6):2178-2185.
44. 2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28(2):402-412.
45. Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O'Leary OF, Castren E, Maffei L (2008) The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 320(5874):385-388.
46. Mayorga AJ, Dalvi A, Page ME, Zimov-Levinson S, Hen R, Lucki I (2001) Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. J Pharmacol Exp Ther 298(3):1101-1107.
47. Melas PA, Rogdaki M, Lennartsson A, Bjork K, Qi H, Witasp A, Werme M, Wegener G, Mathe AA, Svenningsson P, Lavebratt C (2012) Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. Int J Neuropsychopharmacol 15(5):669-679.
48. Menke A, Klengel T, Binder, EB (2012) Epigenetics, depression and antidepressant treatment. Curr Pharm Des (in press).
49. 11C]DASB positron emission tomography study. Am J Psychiatry 161(5):826-835.
50. Millan MJ (2009) Dual-and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 6(1):53-77.
51. 2C receptor activation prevents stress-induced enhancement of brain 5-HT turnover and extracellular levels in the mouse brain: modulation by chronic paroxetine treatment. J Neurochem 115(2):438-449.
52. Murrough JW (2012) Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther 91(2):303-309.
53. Nathan PJ, Cobb SR, Lu B, Bullmore ET, Davies CH (2011) Studying synaptic plasticity in the human brain and opportunities for drug discovery. Curr Opin Pharmacol 11(5):540-548.
54. Nibuya M, Morinobu S, Duman RS (1995) Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15(11): 7539-7547.
55. Ogren SO, Fuxe K (1985) Effects of antidepressant drugs on serotonin receptor mechanisms. Neuropharmacology of serotonin. Oxford University Press, Oxford 131-180.
56. Okamoto H, Voleti B, Banasr M, Sarhan M, Duric V, Girgenti MJ, Dileone RJ, Newton SS, Duman RS (2010) Wnt2 expression and signaling is increased by different classes of antidepressant treatments. Biol Psychiatry 68(6):521-527.
57. Pei Q, Zetterstrom TS, Sprakes M, Tordera R, Sharp T (2003) Antidepressant drug treatment induces Arc gene expression in the rat brain. Neuroscience 121(4):975-982.
58. Portella MJ, de Diego-Adelino J, Ballesteros J, Puigdemont D, Oller S, Santos B, Alvarez E, Artigas F, Perez V (2011) Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry 72(7):962-969.
59. Queree P, Peters S, Sharp T (2009) Further pharmacological characterization of 5-HT(2C) receptor agonist-induced inhibition of 5-HT neuronal activity in the dorsal raphe nucleus in vivo. Br J Pharmacol 158(6):1477-1485.
60. Rabiner EA, Gunn RN, Castro ME, Sargent PA, Cowen PJ, Koepp MJ, Meyer JH, Bench CJ, Harrison PJ, Pazos A, Sharp T, Grasby PM (2000) Beta-blocker binding to human 5-HT(1A) receptors in vivo and in vitro: implications for antidepressant therapy. Neuropsychopharmacology 23(3):285-293.
61. Ren-Patterson RF, Cochran LW, Holmes A, Lesch KP, Lu B, Murphy DL (2006) Genderdependent modulation of brain monoamines and anxiety-like behaviors in mice with genetic serotonin transporter and BDNF deficiencies. Cell Mol Neurobiol 26(4-6):755-780.
62. 18F]MPPF in the nucleus raphe dorsalis of rat. J Neurosci 24(23):5420-5426.
63. 1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 65(1):40-52.
64. Ruhe HG, Mason NS, Schene AH (2007) Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 12(4):331-359.
65. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E, Agerman K, Haapasalo A, Nawa H, Aloyz R, Ernfors P, Castren E (2003) Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressantinduced behavioral effects. J Neurosci 23(1):349-357.
66. Sanacora G, Berman RM, Cappiello A, Oren DA, Kugaya A, Liu N, Gueorguieva R, Fasula D, Charney DS (2004) Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response. Neuropsychopharmacology 29(6):1166-1171.
67. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301(5634):805-809.
68. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122(5):509-522.
69. Schmidt EF, Warner-Schmidt JL, Otopalik BG, Pickett SB, Greengard P, Heintz N (2012) Identification of the cortical neurons that mediate antidepressant responses. Cell 149(5):1152-1163.
70. Scorza MC, Llado-Pelfort L, Oller S, Cortes R, Puigdemont D, Portella MJ, Perez-Egea R, Alvarez E, Celada P, Perez V, Artigas F (2012) Preclinical and clinical characterization of the selective serotonin-1A receptor antagonist DU-125530 for antidepressant treatment. Br J Pharmacol (in press).
71. Serres F, Millan MJ, Sharp T (2012) Molecular adaptation to chronic antidepressant treatment: evidence for a more rapid response to the novel alpha(2)-adrenoceptor antagonist/5-HT-noradrenaline reuptake inhibitor (SNRI), S35966, compared to the SNRI, venlafaxine. Int J Neuropsychopharmacol 15(5):617-629.
72. Sharp T, Boothman L, Raley J, Queree P (2007) Important messages in the 'post': recent discoveries in 5-HT neurone feedback control. Trends Pharmacol Sci 28(12):629-636.
73. Sharp T, Cowen PJ (2011) 5-HT and depression: is the glass half-full? Curr Opin Pharmacol 11(1):45-51.
74. Sillaber I, Panhuysen M, Henniger MS, Ohl F, Kuhne C, Putz B, Pohl T, Deussing JM, Paez-Pereda M, Holsboer F (2008) Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology (Berl) 200(4):557-572.
75. Stahl SM, Palazidou L (1986) The pharmacology of depression: studies of neurotransmitter receptors lead the search for biochemical lesions and new drug therapies. Trends Pharmacol Sci 9:349-354.
76. 1B receptor function by p11 in depression-like states. Science 311(5757):77-80.
77. 6 receptor stimulation. J Neurosci 27(15):4201-4209.
78. Szumlinski KK, Ary AW, Lominac KD (2008) Homers regulate drug-induced neuroplasticity: implications for addiction. Biochem Pharmacol 75(1):112-133.
79. Tardito D, Musazzi L, Tiraboschi E, Mallei A, Racagni G, Popoli M (2009) Early induction of CREB activation and CREB-regulating signalling by antidepressants. Int J Neuropsychopharmacol 12(10):1367-1381.
80. Thome J, Sakai N, Shin K, Steffen C, Zhang YJ, Impey S, Storm D, Duman RS (2000) cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 20(11):4030-4036.
81. Tordera RM, Pei Q, Sharp T (2005) Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment. J Neurochem 94(4):875-883.
82. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ (2006) Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9(4):519-525.
83. Tyrer P, Marsden CA (1985) New antidepressant drugs: is there anything new they tell us about depression? Trends Neurosci 8:427-431.
84. Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11(9):642-651.
85. Warner-Schmidt JL, Duman RS (2008) VEGF as a potential target for therapeutic intervention in depression. Curr Opin Pharmacol 8(1):14-19.
86. Whale R, Terao T, Cowen P, Freemantle N, Geddes J (2010) Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacol 24(4):513-520.
87. Yanpallewar SU, Fernandes K, Marathe SV, Vadodaria KC, Jhaveri D, Rommelfanger K, Ladiwala U, Jha S, Muthig V, Hein L, Bartlett P, Weinshenker D, Vaidya VA (2010) Alpha2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment. J Neurosci 30(3):1096-1109.